(Press-News.org) Among patients with prehypertension and coronary artery disease, use of the renin (an enzyme secreted by the kidneys) inhibitor aliskiren, compared with placebo, did not result in improvement or slowing in the progression of coronary atherosclerosis, according to a study published by JAMA. The study is being released early online to coincide with its presentation at the European Society of Cardiology Congress 2013.
"Guidelines recommend blood pressure reduction in patients with hypertension with a treatment goal of 140 mm Hg for systolic and 90 mm Hg diastolic blood pressure for most individuals. The benefit of additional blood pressure lowering agents in patients who have reached treatment goals has not been established. However, few trials have examined the benefits and risks of further intensifying blood pressure treatment in patients with established coronary artery disease (CAD), who are in the prehypertension range. Preclinical data demonstrate that renin-angiotensin-aldosterone system (RAAS) activation plays an important role in atherosclerosis and that RAAS inhibition may have a direct beneficial effect on the artery wall," according to background information in the article. "Blood pressure reduction and RAAS inhibition are targets for treatment of atherosclerosis. The effect of renin inhibition on coronary disease progression has not been investigated."
Stephen J. Nicholls, M.B.B.S., Ph.D., of the South Australian Health and Medical Research Institute, Adelaide, Australia, and colleagues conducted a study to determine if renin inhibition with aliskiren would slow progression of coronary atherosclerosis in patients whose blood pressure was considered optimally controlled to current treatment targets. The randomized, multicenter trial compared aliskiren with placebo in 613 participants with coronary artery disease, systolic blood pressure between 125 and 139 mm Hg (prehypertension range), and 2 additional cardiovascular risk factors. The trial was conducted at 103 academic and community hospitals in Europe, Australia, and North and South America (enrollment from March 2009 to February 2011; end of follow-up was January 2013).
Participants underwent coronary intravascular ultrasound (IVUS) imaging and were randomized to receive 300 mg of aliskiren (n = 305) or placebo (n = 308) daily for 104 weeks. Disease progression was measured by repeat IVUS examination after at least 72 weeks of treatment, with evaluable imaging data available at follow-up in 74.7 percent of patients (225 in the aliskiren group and 233 in the placebo group). The primary efficacy parameter was the change in percent atheroma (a fatty deposit) volume (PAV) from baseline to study completion.
The researchers found that there was no difference between the treatment groups with respect to measures of atheroma burden at baseline. The primary efficacy measure, PAV, decreased by 0.33 percent in the aliskiren group and increased by 0.11 percent in the placebo group (between-group difference, -0.43 percent). There were no significant differences in the proportion of participants who demonstrated regression of PAV (56.9 percent vs. 48.9 percent) and total atheroma volume (64.4 percent vs. 57.5 percent) in the aliskiren and placebo groups, respectively.
A greater number of discontinuations of participation due to adverse events were observed in the aliskiren group compared with the placebo group (8.2 percent vs. 4.5 percent, respectively).
"These findings do not support the use of aliskiren for regression or prevention of progression of coronary atherosclerosis," the authors conclude.
(doi:10.l001/jama.2013.277169; Available pre-embargo to the media at http://media.jamanetwork.com)
Editor's Note: The study was funded by Novartis Pharmaceuticals. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, etc.
Editorial: Renin-Angiotensin System Inhibition and Secondary Cardiovascular Prevention
In a related editorial, Jean-Claude Tardif, M.D., and Jean Gregoire, M.D., of the Montreal Heart Institute, Montreal, Canada, comment on the findings of this study, and also discuss two other trials in which aliskiren was not effective in improving clinical outcomes in patients with cardiovascular disease.
"Where does this leave inhibition of the renin-angiotensin system for secondary cardiovascular prevention? Angiotensin-converting enzyme inhibitors or, if not tolerated, angiotensin receptor blockers provide clinical benefits and should continue being prescribed to improve outcomes in patients with coronary artery disease. Until additional evidence is available, the role of renin inhibition in this context should be limited. Because aliskiren does reduce blood pressure, perhaps this agent could be reserved for use in patients with coronary disease and hypertension who cannot tolerate ACE inhibitors and angiotensin receptor blockers."
(doi:10.l001/jama.2013.277170; Available pre-embargo to the media at http://media.jamanetwork.com)
Editor's Note: Please see the article for additional information, including financial disclosures, funding and support, etc.
###
Medication does not slow progression of coronary disease in patients with prehypertension
2013-09-03
ELSE PRESS RELEASES FROM THIS DATE:
Lessons from the worm: How the elderly can live an active life
2013-09-03
ANN ARBOR—When the tiny roundworm C. elegans reaches middle age—at about 2 weeks old—it can't quite move like it did in the bloom of youth. But rather than imposing an exercise regimen to rebuild the worm's body-wall muscles, researchers can bring the wriggle back by stimulating the animal's neurons. And, they say, pharmaceuticals might have a similar effect in mammals.
Scientists at the University of Michigan's Life Sciences Institute and Medical School have found that the loss of motor ability associated with aging begins in neurons and spreads to muscles, and that ...
Scientists fish for new epilepsy model and reel in potential drug
2013-09-03
According to new research on epilepsy, zebrafish have certainly earned their stripes. Results of a study in Nature Communications suggest that zebrafish carrying a specific mutation may help researchers discover treatments for Dravet syndrome (DS), a severe form of pediatric epilepsy that results in drug-resistant seizures and developmental delays.
Scott C. Baraban, Ph.D., and his colleagues at the University of California, San Francisco (UCSF), carefully assessed whether the mutated zebrafish could serve as a model for DS, and then developed a new screening method ...
Risk factors help predict outcomes for children with rare heart condition
2013-09-03
A long-term study of children with a complex heart condition called hypertrophic cardiomyopathy (HCM) found that the risk of death or need for immediate listing for heart transplantation was greatest for those who developed this disease as infants with congestive heart failure and for children who also had selective inborn errors of metabolism, a group of rare genetic disorders in which one or more of the body's key metabolic processes are disrupted.
The findings will be published online Tuesday in The Lancet to coincide with a presentation at the European Society of ...
Being underweight increases death risk of CAD women by 2-fold
2013-09-03
Amsterdam, The Netherlands – Tuesday 3 September 2013: Being underweight increases the death risk of women with coronary artery disease (CAD) by 2-fold, according to research presented at the ESC Congress today by Dr Aziza Azimi from Denmark. The study suggests that underweight women with CAD should gain weight to reduce their risk of death.
Dr Azimi said: "The increasing prevalence of obesity is concerning because it is a major risk factor for cardiovascular disease, early death and other diseases like diabetes mellitus type 2, high blood pressure, and high cholesterol. ...
Infections cause lower proportion of lead extractions than expected
2013-09-03
Amsterdam, The Netherlands – Tuesday 3 September 2013: Infections cause a lower proportion of lead extractions than expected, according to preliminary results from the ELECTRa Registry presented at ESC Congress 2013 today by Dr Maria Grazia Bongiorni from Italy.
The European Lead Extraction ConTRolled (ELECTRa) Registry is the first large prospective, multicentre, European controlled registry of consecutive patients undergoing transvenous lead extraction (TLE) procedures in European real world practice. It is carried out by the European Heart Rhythm Association (EHRA) ...
Advancing graphene for post-silicon computer logic
2013-09-03
RIVERSIDE, Calif. — A team of researchers from the University of California, Riverside's Bourns College of Engineering have solved a problem that previously presented a serious hurdle for the use of graphene in electronic devices.
Scanning electron microscopy image of graphene device used in the study. The scale bar is one micrometer. The UCR logo next to it is implemented with etched graphene.
Graphene is a single-atom thick carbon crystal with unique properties beneficial for electronics including extremely high electron mobility and phonon thermal conductivity. However, ...
Size really does not matter when it comes to high blood pressure
2013-09-03
Removing one of the tiniest organs in the body has shown to provide effective treatment for high blood pressure. The discovery, made by University of Bristol researchers and published in Nature Communications, could revolutionise treatment of the world's biggest silent killer.
The carotid body — a small nodule (no larger than a rice grain) found on the side of each carotid artery — appears to be a major culprit in the development and regulation of high blood pressure.
Researchers, led by British Heart Foundation (BHF)-funded researcher Professor Julian Paton, found ...
Revolving images and multi-image keys open new horizons in descriptive taxonomy
2013-09-03
Only a fraction of the biodiversity on the planet is known to scientists and exploration of new places and habitats continue to yield exciting discoveries and new species to describe by taxonomists. This task is becoming increasingly urgent as a function of the continuous overexploitation of natural resources and destruction of habitats. In fact, it has recently been estimated that it takes on average 21 years from the discovery of a species in nature to its formal scientific description. The 'shelf life' can sometimes be significantly longer, as for the millipede Ommatoiulus ...
Research confirms Mediterranean diet is good for the mind
2013-09-03
The first systematic review of related research confirms a positive impact on cognitive function, but an inconsistent effect on mild cognitive impairment
Over recent years many pieces of research have identified a link between adherence to a Mediterranean diet and a lower risk of age-related disease such as dementia.
Until now there has been no systematic review of such research, where a number of studies regarding a Mediterranean diet and cognitive function are reviewed for consistencies, common trends and inconsistencies.
A team of researchers from the University ...
Life without insulin is possible
2013-09-03
Several millions of people around the world suffer from insulin deficiencies. Insulin is a hormone, secreted by the beta cells in the pancreas, which plays a major role in the regulation of energy substrates such as glucose. This insufficiency, primarily caused by diabetes (types 1 and 2), has lethal consequences if it is not treated. As of now, only daily insulin injections allow patients to survive.
Several millions of people around the world suffer from insulin deficiencies. Insulin is a hormone, secreted by the beta cells in the pancreas, which plays a major role ...